^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Melanoma
    Drug:PLX4720 (BRAF inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR-II 2020
    Title:

    Abstract 3415: Mutant BRAF small molecule inhibition enhances oncolytic herpes virus immunotherapy through increased immune cell recruitment and activation in melanoma

    Published date:
    05/15/2020
    Excerpt:
    ...we show that the combination of PLX4720 (BRAFV600E inhibitor) and intratumoral oncolytic herpes virus HSV1716 led to a significant tumor reduction and improved survival over single-agent treatment in a murine BRAFV600E melanoma model.
    Secondary therapy:
    HSV1716
    DOI:
    10.1158/1538-7445.AM2020-3415